Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review

(2020) Kenneth H. Mayer et al.   ADVANCES IN THERAPY

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

(2020) Kenneth H Mayer et al.   LANCET

Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate

(2019) Samir K. Gupta et al.   AIDS

Efficacy of oral tenofovir alafenamide/emtricitabine combination or single agent tenofovir alafenamide against vaginal SHIV infection in macaques

(2019) Ivana Massud et al.   JOURNAL OF INFECTIOUS DISEASES

The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States

(2018) Aaron J. Siegler et al.   ANNALS OF EPIDEMIOLOGY

Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine

(2018) David V Glidden et al.   CLINICAL INFECTIOUS DISEASES

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

(2018) Raphael J. Landovitz et al.   PLOS MEDICINE

Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study

(2018) Andrew E Grulich et al.   Lancet HIV

Brief Report

(2017) José R. Arribas et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials

(2016) Dobromir T. Dimitrov et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations

(2016) C. M. Weaver et al.   OSTEOPOROSIS INTERNATIONAL

Tenofovir and bone health

(2016) Philip M. Grant et al.   Current Opinion in HIV and AIDS

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

(2013) Peter J. Ruane et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Diet quality and weight gain among black and white young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study (1985–2005)

(2010) Daisy Zamora et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers

(2010) Paul A Randell et al.   ANTIVIRAL THERAPY

Lack of Effect of Tenofovir Disoproxil Fumarate on Pharmacokinetics of Hormonal Contraceptives

(2009) Brian P Kearney et al.   PHARMACOTHERAPY

Lumbar spine peak bone mass and bone turnover in men and women: a longitudinal study

(2008) J. S. Walsh et al.   OSTEOPOROSIS INTERNATIONAL